Etanercept

依那西普

Report date: 2026/03/31 20:00:21

Base Information

Drug NameEtanercept
Drug Alias NameTNFR:FcRhu TNFR-FcTNFR-Fc-p75TNF receptor fusion proteinRhTNFR:Fc +[12] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisRejection of lung transplantationNon-radiographic axial spondyloarthritis +[47] 
Global Approved IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[6] 
Approved Indications in ChinaPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryEU
Original Approved Date2000/02/02
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen IncPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgPfizer IncWayne State University +[6] 
Inactive CompaniesUtah State UniversityWyeth LlcUniversity Of Medicine And Dentistry Of New Jersey +[33] 
Active IndicationsPlaque psoriasisRejection of lung transplantationPsoriasis +[8] 
Inactive IndicationsNon-radiographic axial spondyloarthritisSolid tumoursAnorexia +[39] 

Other Information

ATC CodeL04AB01
Related LinksWikipediaDrugBankKEGG